Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07111559 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial

Study acronym: LACUNAR-tPA
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 28 to 29v10
  2. Study sites: 27 to 28v9
  3. Study sites: 24 to 27v8
  4. Study sites: 18 to 24v7
  5. Study sites: 13 to 18v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 9 to 13v5
  2. Study sites: 5 to 9v4
  3. Study sites: 2 to 5v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Eligibility criteria shortened, about 7 words
    • Secondary endpoints expanded, about 29 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn if a combination of antiplatelet drugs works better than intravenous tissue plasminogen activator to treat small ischemic stroke (lacunar stroke). The main questions it aims to answer are: Is a combination of antiplatelet drugs non-inferior to the current standard tissue plasminogen activator treatment? Does a combination of antiplatelet drugs reduce the bleeding complications than tissue plasminogen activator? Researchers will compare a combination of antiplatelet drugs to tissue plasminogen activator to see if a combination of antiplatelet drugs works to treat small ischemic stroke (lacunar stroke). Participants will: Take a combination of antiplatelet drugs or be given intravenous tissue plasminogen activator Check the neurological status 3 months after stroke, in-person, by phone, or by mail.
Trial Details
NCT Number NCT07111559
Lead Sponsor Nippon Medical School
Collaborators: Japan Research Foundation for Clinical Pharmacology, Takeda Science Foundation - Medical Research Grant
Conditions
(from sponsor)		 Lacunar Stroke, Stroke, Ischemic Stroke
Related terms Ischemic Stroke, Stroke, Stroke, Lacunar
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov